1. Home
  2. ARTL vs MTNB Comparison

ARTL vs MTNB Comparison

Compare ARTL & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ARTL

Artelo Biosciences Inc.

N/A

Current Price

$3.45

Market Cap

2.5M

Sector

Health Care

ML Signal

N/A

Logo Matinas Biopharma Holdings Inc.

MTNB

Matinas Biopharma Holdings Inc.

SELL

Current Price

$2.98

Market Cap

2.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ARTL
MTNB
Founded
2011
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.6M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
ARTL
MTNB
Price
$3.45
$2.98
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 1.3M
483.2K
Earning Date
11-11-2026
08-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 59.84
EPS
N/A
★ N/A
Revenue
N/A
★ $119,750.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.52
$0.15
52 Week High
$19.91
$3.05

Technical Indicators

Market Signals
Indicator
ARTL
MTNB
Relative Strength Index (RSI) 45.55 84.84
Support Level $3.20 $0.40
Resistance Level $6.81 N/A
Average True Range (ATR) 1.26 0.19
MACD -0.30 0.29
Stochastic Oscillator 0.16 93.32

Price Performance

Historical Comparison
ARTL
MTNB

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

About MTNB Matinas Biopharma Holdings Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

Share on Social Networks: